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Abstract
This study examined the association of menstrual cycle phase with stress reactivity as well as the
hormonal and neuroendocrine mechanisms contributing to cycle effects. Fifty-seven women
underwent a modified Trier Social Stress Test (TSST) during the early follicular, late follicular
and luteal phases of the menstrual cycle. Greater increases in cardiac index (CI) and greater
decreases in vascular resistance index (VRI) during speech were observed in the luteal phase
relative to other phases, while greater increases in epinephrine (EPI) was observed during the late
follicular and luteal phases compared to the early follicular phase. Luteal phase estradiol predicted
luteal EPI reactivity but not CI or VRI reactivity while luteal phase EPI reactivity predicted luteal
phase CI and VRI reactivity. Thus, cycle-related changes in EPI reactivity may be a stronger
determinant of cycle effects on hemodynamic reactivity than sex hormones per se.
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Cardiovascular disease (CVD) is the leading cause of mortality for women in the United
States (Center for Disease Control, 2009). However, women are relatively protected from
CVD until they reach the menopause transition, after which they experience a doubling of
their CVD risk (Gordon, Kannel, Hjortland, & McNamara, 1978). That young women
experiencing premature ovarian failure also exhibit an increased risk for CVD (Hu et al.,
1999; Jacobsen, Knutsen, & Fraser, 1999) strongly suggests that sex steroid hormone
withdrawal, independent of advancing age, is responsible for this observation.
Female sex hormones may act to confer CVD protection in part via beneficially modifying
physiologic reactivity to stress. Exaggerated stress reactivity has been shown to predict the
development of CVD risk factors, including hypertension, increased left ventricular mass,
carotid atherosclerosis and coronary calcification (Gianaros et al., 2005; Matthews et al.,
2004; Treiber et al., 2000) as well as future CVD risk itself (Chida & Steptoe, 2010).
Among postmenopausal women, combined estrogen and progesterone therapy lowers blood
pressure (BP) reactivity to stress and beneficially modifies the hemodynamic and
neuroendocrine determinants of BP reactivity, namely vascular resistance stress reactivity,
endothelial function, and norepinephrine stress reactivity (Del Rio et al., 1998; Girdler et al.,
2004; Light et al., 2001). While these studies suggest that estrogen and progesterone may
serve to protect premenopausal women from CVD via their positive effect on cardiovascular
*Corresponding author at: Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, CB# 7160, 101




Psychophysiology. Author manuscript; available in PMC 2015 April 01.
Published in final edited form as:













and neuroendocrine stress reactivity, with few exceptions, the majority of these studies have
examined combined (estrogen plus progesterone) therapy and therefore cannot differentiate
the cardioprotective effects of estrogen from progesterone.
Studies in premenopausal women that have attempted to do so by examining stress reactivity
at different phases of the menstrual cycle have yielded inconsistent findings (Childs, Dlugos,
& DeWit, 2010; Kirschbaum, Kudielka, Gaab, Schommer, & Hellhammer, 1999; Lustyk,
Douglas, Shilling, & Woods, 2012; Lustyk, Olson, Gerrish, Holder, & Widman, 2010;
Manhem, Jern, Pilhall, Shanks, & Jern, 1991; Polefrone & Manuck, 1988; Pollard et al.,
2007), that may be attributable to at least two methodological limitations in the existing
research. First, these studies have compared stress reactivity in the luteal phase,
characterized by elevated estradiol and progesterone, with reactivity in the follicular phase,
assumed to reflect a lower hormone state. However, only the early follicular phase is
characterized by both low estradiol and progesterone while the mid to late follicular phase is
associated with markedly elevated estradiol concentrations. Thus, the existing menstrual
cycle literature, with one exception (Pollard et al., 2007), is unable to differentiate the
influence of estradiol alone from estradiol plus progesterone on stress reactivity. Pollard et
al., (2007) showed that HR reactivity to perceived work stress is greater in the late follicular
phase compared to the early follicular phase, underscoring the importance of refining the
follicular phase window of testing.
The second major limitation of many of the referred menstrual cycle studies is the reliance
on a between-subjects design. The substantial inter-individual differences in absolute sex
steroid concentrations across the menstrual cycle obscures the ability to examine menstrual
cycle phase effects on stress reactivity with a between-subjects design (Gravetter & Forzano,
2011).
These limitations notwithstanding, the majority of studies in this field find an absence of
menstrual cycle effects on BP reactivity to stress (Collins, Eneroth, & Landgren, 1985;
Girdler & Light, 1994; Girdler, Pedersen, Stern, & Light, 1993; Kajantie & Phillips, 2006;
Stoney, Langer, & Gelling, 1986; Stoney, Owens, Matthews, Davis, & Caggiula, 1990).
That is not to say, however, that the menstrual cycle does not influence the underlying
hemodynamic determinants of BP reactivity, namely stroke volume (SV), cardiac output
(CO) and vascular resistance (VR). The relative contribution that the myocardium versus the
vasculature makes to BP responses, which is relatively stable within an individual over time
(Kasprowicz, Manuck, Malkoff, & Krantz, 1990; Sherwood, Turner, Light, & Blumenthal,
1990), may be an important pathogenic influence in CVD development (Manuck, 1990).
Estradiol has been shown to exert inotropic (contractile) actions on the myocardium, thereby
increasing SV (Girdler et al., 2004; Pines et al., 1991; Ren et al., 2003), and to promote
greater vasodilation to stress, thereby decreasing VR (Girdler, et al., 2004; Pines, et al.,
1991). This combination of enhanced myocardial reactivity and greater decreases in VR is a
hemodynamic stress response profile seen in groups at lower risk for CVD relative to their
higher risk counterparts (Allen, Stoney, Owens, & Matthews; Girdler, Turner, Sherwood, &
Light, 1990; Light, Turner, Hinderliter, & Sherwood, 1993; Sherwood, & Light, 1990;
Treiber et al., 2000). Moreover, greater VR contributes to left ventricular hypertrophy (D.
Levy et al., 1988), an independent predictor of CVD morbidity/mortality (Ghali et al., 1992;
Koren, Devereux, Casale, Savage, & Laragh, 1991).
To date, there have been only four studies examining menstrual cycle influences on
hemodynamic stress reactivity. In two prior within-subjects studies from our group, the
luteal phase was associated with greater increases in SV coupled with greater decreases in
VR to mental stress relative to the early follicular phase (Girdler & Light, 1994; Girdler, et
al., 1993). The third study (McFetridge & Sherwood, 2000), using a between-subjects
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design, similarly found greater decreases in VR to mental stress during the luteal compared
to the early follicular phase, though SV did not differ. Finally, in the fourth study (Sita &
Miller, 1996), a within-subjects design, there were no differences in SV, CO or VR between
the luteal phase and the late follicular phase. However, the relative equivalence of estradiol
concentrations in luteal and late follicular phases may have accounted for the absence of a
phase effect in that study.
The influence of the endogenous steroid hormones on hypothalamic-pituitary-adrenal (HPA)
axis and sympatho-adrenal axis reactivity is also relevant to CVD risk (Christensen &
Schultz-Larsen, 1994; Whitworth, Williamson, Mangos, & Kelly, 2005; Zoccali et al.,
2002). Where phase effects on HPA axis reactivity have been observed, cortisol reactivity,
but not ACTH reactivity, is greater in the luteal than the follicular phase (Childs, et al.,
2010; Kirschbaum, et al., 1999). While fewer studies on catecholamine stress reactivity
across the menstrual cycle exist, the data suggest greater catecholamine resting levels
(Girdler et al., 2003) and reactivity in the luteal versus the early to mid-follicular phase
(Childs, et al., 2010; Collins, et al., 1985). Exceptions to this general finding do exist,
however: for example, one study by McFetridge & Sherwood (2000) found that women in
the luteal phase exhibited lower catecholamine responses to laboratory stressors compared to
women in the follicular phase.
Finally, no studies of which we are aware have examined the hormonal and neuroendocrine
predictors of hemodynamic stress reactivity across the menstrual cycle. Thus, it is unknown
whether estradiol and progesterone influence hemodynamic reactivity directly or indirectly
(e.g., through alterations in neuroendocrine reactivity). The aims of the present study were
therefore: 1) to examine menstrual cycle effects on hemodynamic and neuroendocrine stress
reactivity in the early follicular (low hormones), late follicular (high estradiol, low
progesterone) and luteal (high estradiol and high progesterone) phases of the menstrual
cycle; and 2) to explore the hormonal and neuroendocrine predictors of these effects.
Method
Participants
Participants included 57 women who were medically healthy non-smokers, aged 18–40,
recruited through newspaper advertisements. Exclusion criteria included: blood pressure
>160/90 mmHg, prescription medication use (including oral contraceptives), regular over-
the-counter medication use (e.g., non-steroidal anti-inflammatory agents), a chronic pain
condition (e.g. temporomandibular joint disorder, fibromyalgia, arthritis) or other medical
illness (e.g. cardiovascular, respiratory, neuroendocrine and gastrointestinal disorders),
irregular menstrual cycles (<24 days or >32), self-reported alcoholism or drug abuse, a
history of more than one depressive episode, the presence of a depressive episode in the last
year, or self-reported moderate to severe emotional premenstrual symptoms. Due to the
association of both depression (Gordon et al., 2008) and anxiety (Watkins, Blumenthal, &
Carney, 2002) with cardiac-autonomic dysfunction, participants with Hamilton Depression
Scale scores > 7 or Hamilton Anxiety scores > 9 (administered by a trained interviewer)
were excluded., The study protocol was approved by the institution’s Institutional Review
Board. All participants provided informed, written consent prior to participating and
received $150 in compensation.
Procedure
All laboratory sessions began at 8:00 a.m. Participants were asked to refrain from all over-
the-counter medications 24 hours before testing as well as refrain from caffeine the day of
testing. Participants were tested at three time points throughout their menstrual cycle (Figure
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1): the early follicular phase (days 1–4, when both estradiol and progesterone are low), the
late follicular phase (days 9–12, when estradiol is elevated and progesterone is low) and the
luteal phase (5–10 days after ovulation, when both estradiol and progesterone are elevated).
The timing of the luteal phase was based upon the detection of the luteinizing hormone (LH)
surge that occurs 24–36 hours prior to ovulation using a home urine ovulation predictor test.
All cycles were later confirmed to be ovulatory based on serum progesterone and estradiol
levels, taken during the baseline period of each testing session (Table 1). The order of
menstrual cycle phase was randomized for each woman.
Upon arrival, participants were instrumented with a BP cuff and impedance band electrodes
for later monitoring of cardiovascular stress reactivity. A catheter was then placed into a
forearm vein, to be used for blood draws using a non-heparinized, multi-stop-cock system
allowing for blood samples to be taken at precise time intervals throughout testing. A curtain
was drawn to prevent the subject from viewing the catheter and the blood draws.
A secondary goal of the current study was to examine the effect of the menstrual cycle on
pain sensitivity to a short battery of pain tests. These results are reported elsewhere
(Klatzkin, Mechlin, & Girdler, 2010). Thus, subjects were exposed to both a mental stressor
battery and a pain testing battery. The order of stress and pain testing was counterbalanced
across subjects but constant within subject (see Figure 2).
Figure 2 depicts the sequence of laboratory events: 1) Instrumentation and intravenous set-
up; 2) recovery from venipuncture (15 min); 3) baseline (10 min quiet rest); 4) Trier social
stress test (TSST) (23.5 min); 5) recovery (10 min); 6) pain testing; 7) rest control (or TSST
if event #4 was rest control) (23.5 min); 8) recovery (10 min); and 9) pain testing. The
current study’s findings are based on events #3, #4 and #5 for those who had the TSST first,
or events #3, #7 and #8 for those who had pain testing first. These events are described
below.
Baseline
Twenty-five minutes of quiet rest followed the i.v. setup, the first 15 min being recovery
from venipuncture and the final 10 min constituting baseline. Blood pressure and
impedance-derived measures were taken at minutes 1, 3, 6, 8 and 10 and averaged to yield a
mean baseline value. Blood was sampled at minute 10 for baseline ACTH, cortisol,
epinephrine (EPI), norepinephrine (NE), estradiol and progesterone concentrations.
The Trier Social Stress Test (TSST)
The TSST used was modified to account for the fact that participants were not ambulatory
and to include a serial addition rather than a serial subtraction task. The TSST is a stress test
that has been shown to induce reliably large and consistent activation of the SNS and HPA
axes (Kirschbaum, Pirke, & Hellhammer, 1993). The TSST involves four components: 1)
Pre-task instructions (5 minutes) during which participants are introduced to the committee
who will later listen to their job talk, and are given instructions for the mental arithmetic
task; 2) Speech preparation period (5 minutes) during which time participants were left
alone to prepare their job talk; 3) Job speech (5 minutes) immediately following the
preparation period, the selection committee returned to the testing room and asked the
participant to deliver his/her job talk on why they would be the perfect candidate for the job.
If the participant ended their talk before 5 minutes, the selection committee questioned the
participant in a systematic fashion to ensure the participant would speak the entire 5
minutes. Participants were tape-recorded throughout their performance. 4) Paced auditory
serial addition test (PASAT) (8.5 minutes) involves a tape-recorded presentation of numbers
from 1 to 9 (for greater detail, see Tombaugh, 2006). Participants added each number
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presented on the tape to the immediately preceding number and stated the answer aloud.
There are four series of numbers, with progressively shorter inter-digit intervals. The
committee remained in the room to monitor performance.
Cardiovascular measures were obtained at minutes 1, 3 and 5 of both the speech preparation
period and the job speech and once during each of the four series of the PASAT. These
measures were then averaged to obtain a mean preparation, speech and math task value for
each cardiovascular measure. Plasma EPI and NE were sampled at the end of minute 2 of
both the job speech and PASAT since catecholamines peak within the first two minutes of
mental stress (Dimsdale & Ziegler, 1991).
Post-Stress Cortisol Sampling
Participants rested quietly alone. Plasma cortisol was measured at the end of the recovery
period to capture the delayed plasma cortisol response to the TSST (Kirschbaum, Klauer,
Filipp, & Hellhammer, 1995; Kirschbaum et al., 1995).
Physiological Recording Procedures
The SunTech Exercise BP monitor, Model 4240 (SunTech Medical Instruments, Inc.,
Raleigh, NC) provided BP measurements during baseline and mental stress testing. Five
standard stethoscopic and automated BP measurements were taken simultaneously to ensure
correct microphone placement and cuff position.
Impedance cardiography was used to noninvasively monitor cardiovascular activity
(Sherwood et al., 1990), including CO, SV, total vascular resistance (VR) and HR. A
custom-designed impedance cardiograph (HIC-100 Bioimpedance Technology, Inc., Model
100, Chapel Hill, NC, USA) was used in conjunction with a tetrapolar band electrode
configuration to record impedance dZ/dt and Zo signals. Impedance and electrocardiogram
signals were processed online by specialized computer software (BIT, Chapel Hill, NC) with
subsequent manual editing to improve accuracy. For each minute of interest, a 30 second
continuous sample of waveforms (obtained concurrently with BP) was processed to generate
an ensemble-averaged cardiac cycle, from which SV was determined using the Kubicek et
al. (1966) equation and HR was determined using the mean interbeat interval. CO and VR
for these same minutes were then calculated using standard formulae (Sherwood et al.,
1990). CO, SV and VR were adjusted for individual variations in body size by using body
surface areas to derive cardiac index (CI), stroke volume index (SVI) and vascular resistance
index (VRI).
Hormone and Neuroendocrine Assays
Plasma cortisol, serum estradiol and progesterone were determined using radioimmunoassay
(RIA) techniques (ICN Biomedical Inc.). The specificity of the antiserum for progesterone is
very high, showing only 0.01–2.5% cross-reactivity with other steroid compounds. The
specificity of the antiserum for estradiol is also high, showing only 0.01–1.45% cross-
reactivity with steroid hormones with the exception of estrone, for which there is up to 6%
cross-reactivity. For cortisol, the sensitivity of the assay is excellent at 0.07 µg/dl and the
specificity high, showing 0.05–2.2% cross-reactivity with similar compounds, except
prednisolone, where 94% cross-reactivity is obtained.
Plasma ACTH was determined using RIA techniques from commercially available kits
(Nichols Institute Diagnostics). The sensitivity of this assay is high at 1 pg/ml and the
selectivity is excellent showing only 0–0.02% cross-reactivity with steroid compounds.
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Plasma EPI and NE concentrations were determined using the high performance liquid
chromatography (HPLC) technique. All HPLC procedures were conducted in the Core
Laboratory of the institution’s General Clinical Research Center (GCRC). The lower limit of
quantification is 25 pg/ml and the intra- and inter- day coefficients are <10%.
Statistical Analyses
As per Warner (2012), sensitivity analyses were used to identify extreme outliers prior to
data analysis, defined as values 3 or more interquartile ranges below the first quartile or
above the third quartile (SAS Institute Inc., 2011). Although the analyses presented are those
with the outliers removed, analyses with the outliers retained yielded an identical pattern of
results.
For each cardiovascular or neuroendocrine measure, reactivity was defined as the difference
between mean stress level and mean baseline level. T-tests were used to confirm a
significant effect of the TSST on hemodynamic and neuroendocrine measures.
Apart from cortisol and ACTH, which were measured only in response to the TSST,
reactivity of all other measures was calculated separately in response to the job speech and
the PASAT in consideration of the literature suggesting that women are particularly
responsive to social rejection over performance-type tasks (Darnall & Suarez, 2009).
For each physiologic dependent measure, a repeated measures ANOVA, with cycle phase as
the repeated measure was then used to examine phase effects on baseline and reactivity
values in the early follicular, late follicular and luteal phases. Within-subjects paired t-tests
were then used to explore significant phase effects. The Huynh-Feldt correction was used
whenever appropriate to correct for sphericity.
Where significant phase effects on stress reactivity were observed, stepwise regression
analyses were conducted in order to examine predictors of the phase effects. In stepwise
regression each independent variable specified is entered into the regression one at a time
until all variables have been added with the provision that each meets the specified criterion.
For this study, the criterion used was one of significance level p<.100, a more conservative
significance level than the p-value of .150 that is conventional for stepwise regression (SAS
Institute, 2011). Furthermore, the stepwise approach involves an additional procedure in
which all variables are reexamined after the addition of other variables to verify that each
remains a significant and independent predictor. Thus, this approach helps to circumvent the
problem of multicolinearity of independent variables.
All analyses were conducted using SAS v. 9.3.
Results
Participant Characteristics
As reflected in Table 1, the participants were relatively young, had low depression and
anxiety scores and exhibited estradiol and progesterone concentrations in each menstrual
cycle phase that were consistent with expected values.
Menstrual Cycle Effects on Baseline Measures
A significant effect of phase was found for baseline HR (F(2, 98) = 3.91, p = .024) such that
HR during the luteal phase was significantly higher than the early (t(49) = 2.27, p = .027)
and late follicular phase (t(51) = 2.56, p = .014). Second, a significant effect of menstrual
cycle phase was seen for baseline VRI (F(2, 94) = 3.06, p = .052) such that VRI was
significantly lower during the luteal phase compared to the early follicular phase (t(47) =
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−2.14, p = .038). No other baseline cardiovascular or neuroendocrine measures differed
according to menstrual cycle phase.
Overall Efficacy of the Stress Protocol
Systolic BP, Diastolic BP and HR all significantly increased in response to the mental
stressors (t(57) = 21.1, 24.6 and 19.2, p<.001, respectively) as did plasma EPI, NE (t(55) =
6.8 and 6.7, p<.001, respectively), ACTH (t(55) = 2.0, p = .047) and CI (t(55) = 10.6, p<.
001). SVI tended to decrease (t(55) = −1.9, p=.070) while no effect of the mental stress was
seen for VRI or plasma cortisol.
Menstrual Cycle Effects on Stress Reactivity
Blood pressure (BP) and heart rate (HR)—No phase effects on BP or HR reactivity
were observed in response to either mental stressor.
Hemodynamic measures—Menstrual cycle phase effects were seen for CI reactivity
(F(2, 94) = 3.6, p = .033) such that during the speech, reactivity was greater during the luteal
phase than the early follicular phase (t(47) = −2.6, p = .014) (Figure 3). Although the
omnibus test for a cycle effect on VRI reactivity to speech did not reach statistical
significance (F(2, 94) = 2.2, p = .123), because of the prior literature indicating that such an
effect is consistently observed, we compared the individual phases in response to the speech.
Consistent with prior research, VRI decreases in the luteal phase was significantly different
from essentially no change in VRI in the late follicular phase (t(49) = 2.4, p = .019) (Figure
4). No cycle effects were observed for SVI reactivity.
Epinephrine (EPI)—Consistent with the pattern seen for CI reactivity, a significant effect
of menstrual cycle phase was seen for EPI reactivity (F(2, 86) = 3.3, p = .048) such that
reactivity in response to the speech was greater in the late follicular (t(46) = −2.2, p = .031)
and luteal phases (t(45) = −2.7, p =.009) compared to the early follicular phase (Figure 5).
Norepinephrine (NE), ACTH and Cortisol—There were no significant effects of cycle
phase on stress reactivity of these neuroendocrine measures.
Hormonal and Neuroendocrine Predictors of Menstrual Cycle Phase Effects
In order to examine predictors of speech stress reactivity measures that were influenced by
the menstrual cycle (EPI, CI and VRI reactivity), stepwise multiple regression analyses were
conducted. Estradiol, progesterone, baseline and reactivity values for cortisol, EPI and NE
were entered as possible predictors into two separate models, the first predicting CI
reactivity to the speech stress and the second predicting VRI reactivity to the speech stress.
These analyses were conducted separately for each menstrual cycle phase. A third model,
including the same predictors as above, with the exception of baseline and reactivity EPI,
was similarly examined as potential predictors of EPI reactivity for each menstrual cycle
phase (see Table 4).
CI—In the early follicular phase, greater baseline EPI and greater EPI reactivity predicted
greater CI reactivity, accounting for 36% of its variance (F(2, 45) = 11.9, p<.001). In the late
follicular phase, greater EPI reactivity and NE reactivity predicted greater CI reactivity,
accounting for 26% of its variance (F(2, 51) = 8.9, p<.001). Finally, in the luteal phase,
greater EPI reactivity predicted greater CI reactivity, accounting for 43% of its variance
(F(1, 46) = 34.4, p<.001).
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VRI—A significant predictive model was found for VRI reactivity during the luteal, but not
the early or late follicular phases. In this model, both greater luteal EPI reactivity and
baseline NE predicted greater decreases in VRI. Together, they accounted for 17% of the
variance in VRI reactivity (F(2, 46) = 4.4, p = .019).
EPI—In the early follicular phase, greater baseline NE and greater NE reactivity predicted
greater EPI reactivity, accounting for 18% of its variance (F(2, 46) = 4.6, p = .015). In the
late follicular phase, greater NE reactivity predicted greater EPI reactivity and accounted for
34% of its variance (F(1, 52) = 25.9, p<.001). Finally, in the luteal phase, greater
concentrations in luteal phase estradiol and greater NE reactivity and cortisol reactivity
predicted greater EPI reactivity, accounting for 51% of its variance (F(3, 47) = 15.4, p<.
001).
Discussion
The current study aimed to clarify the effects of estradiol versus progesterone in various
phases of the menstrual cycle on stress reactivity as well as to identify the hormonal and
neuroendocrine mechanisms predicting these effects. Results indicated that EPI, CI and VRI
reactivity to stress differ by menstrual phase, with the greatest increases in EPI and CI, and
the greatest decreases in VRI (vasodilatory responses) occurring during the luteal phase,
when both estradiol and progesterone are elevated. While it must be acknowledged that the
overall effect of cycle phase on VRI did not reach conventional levels of statistical
significance, this likely resulted from a Type II error as suggested by our posthoc tests
comparing the luteal and late follicular phases, where differences in VRI were substantial
and statistically significant.
It was found that EPI reactivity increased in the late follicular phase and remained elevated
during the luteal phase, mirroring menstrual increases in estradiol rather than progesterone.
Furthermore, stepwise regression analyses demonstrated that estradiol, but not progesterone,
was an independent predictor of EPI reactivity during the luteal phase, as was cortisol
reactivity, the latter potentially reflecting the positive feedback effects involving the HPA
and SNS axes (Calogero, Gallucci, Chrousos, & Gold, 1988; Valentino, Foote, & Aston-
Jones, 1983). That EPI but not NE reactivity was associated with menstrual cycle phase may
be related to the fact that estradiol and plasma EPI share the adrenal gland as a common
origin whereas NE’s release is more dispersed throughout the body. However, this
explanation is inconsistent with the only other study measuring catecholamine reactivity to
the TSST across the menstrual cycle (Childs et al., 2010), which found NE reactivity to be
greatest in the luteal relative to the early follicular phase. While both the current study and
the study by Childs et al. find greater catecholamine reactivity in the luteal phase, these
cycle effects run counter to the literature examining the effect of exogenous estradiol
administration in perimenopausal (Komesaroff, Esler, & Sudhir, 1999) and postmenopausal
women (Girdler, et al., 2004; Light et al., 2001; Lindheim et al., 1992) and in men (Del Rio
et al., 1994), which find a catecholamine reactivity blunting effect of estradiol.
The human and animal literature suggests that estradiol attenuates reactivity of the
sympatho-adrenal nervous system through a variety of mechanisms (Hinojosa-Laborde,
Chapa, Lange, & Haywood, 1999), including reduced sensitivity of α2 adrenergic receptors
to inhibitory signals (Del Rio, Verlardo, Zizzo, Marrama, & Della Casa, 1993) and
decreased release and increased degradation of catecholamines at the adrenal medulla
(Fernandez-Ruiz, Bukhari, Martinez-Arrieta, Tresguerres, & Ramos, 1988). However, the
estradiol-mediated effects on sympathetic mechanisms that are observed when exogenous
estradiol is delivered in isolation may be less evident in the presence of other hormones or
processes occurring in the late follicular or luteal phases of the menstrual cycle. For
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example, relative to control and estradiol treatment, combined estradiol and progesterone
treatment in postmenopausal women has been associated with greater catecholamine
reactivity to mental stress (Burleson et al., 1998). However, our study found increased EPI
reactivity in the late follicular phase relative to the early follicular phase, suggesting that the
association between elevated estradiol concentrations and increased catecholamine reactivity
is not solely explained by concurrently elevated progesterone concentrations. Clearly, the
context in which reproductive steroid hormones act on the sympathetic nervous system,
including the age, sex, and menopausal status of the individual, is important. Furthermore,
the acute actions of an exogenously-administered hormone may differ from the effects of
long-term endogenous hormone exposure.
In the case of CI, although reactivity was greater during the luteal phase, when both estradiol
and progesterone are elevated, the stepwise regression analyses suggest that the elevated
luteal phase CI reactivity does not result from elevated sex steroid concentrations, but rather
appears to be driven by menstrual cycle increases in EPI reactivity (which was also greater
in the luteal than the early follicular phase). While EPI reactivity also predicted CI reactivity
in the early and late follicular phases, the amount of variance explained in CI reactivity was
substantially lower. The effect of EPI on CI reactivity is consistent with the well-
documented effects of EPI on hemodynamic responses (B. Levy et al., 1997; B. Levy, Perez,
Perny, Thivilier, & Gerard, 2011), and likely occurs through EPI’s stimulation of
myocardial β1 adrenergic receptors, which mediate both inotropic and chronotropic
activities of the myocardium to increase CI.
Similarly for VRI reactivity, the stepwise regression analyses did not support an independent
role of either estradiol or progesterone in driving luteal phase-related changes in VRI
reactivity. Rather, greater luteal phase EPI reactivity and baseline NE concentrations
predicted the vasodilatory responses to stress seen in the luteal phase. However, the
independent modulatory role of catecholamines was weaker for VRI than CI. This is
consistent with the results of McFetridge & Sherwood (2000), who observed exaggerated
luteal-phase decreases in VR in the absence of increased catecholamine reactivity, though
that study was limited by the use of a between-subjects design. Thus, other mechanisms not
directly related to absolute catecholamine concentrations may alter VRI reactivity in the
luteal phase. One possibility relates to the α-adrenoceptors. Catecholamine-induced
stimulation of vascular α-adrenoceptors mediates vasoconstrictive responses (Ahlquist,
1976). Alpha 2-adrenoceptor sensitivity has been found to be reduced in the luteal phase of
the menstrual cycle, at least in White women, though the mechanisms through which this
occurs are unknown (Freedman & Girgis, 2000). If this mechanism were at play, although
EPI release may increase in the luteal phase, its α adrenoceptor-mediated vasoconstrictive
effects may be lessened while its β-adreneroceptor-mediated vasodilatory effects remain
intact, thereby resulting in a net vasodilatory tone. Future studies testing the effect of
adrenergic receptor blockade on stress reactivity throughout the menstrual cycle could help
clarify this issue.
Of note, a menstrual cycle phase effect was found for the speech task but not the math task.
Though participants’ neuroendocrine and cardiovascular responses were in the same
direction for both tasks (Table 2), reactivity was greatest during the speech. The fact that the
math task was modified to involve an addition rather than a subtraction exercise, making the
task easier than the traditional TSST, may be one explanation for the reduced physiological
responses during the math task. The nature of the tasks themselves may also be important:
traditionally, speech stressors have been viewed as more gender relevant for women, while
mental arithmetic stressors may be more gender relevant for men (Darnall & Suarez, 2009).
Thus, the potency and nature of the stressor may unveil a menstrual cycle effect on stress
reactivity, as suggested by previous research using stressors varying greatly in intensity
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(Kajantie & Phillips, 2006). The current study addresses several gaps in the literature on
menstrual cycle and stress reactivity. It used a within-subjects design and is the only
laboratory-based study examining stress reactivity at three key times throughout the
menstrual cycle, thereby examining menstrual cycle effects during three distinct hormonal
milieus. Finally, our simultaneous measurement of both hemodynamic and neuroendocrine
reactivity in the same individuals allowed for the advancement of our current understanding
of neuroendocrine and hormonal mechanisms contributing to myocardial and vascular stress
reactivity in women across the reproductive cycle.
Despite these strengths, the current study should be interpreted in light of its limitations. The
absence of stress or cycle effects on the HPA-axis measures may have resulted from: 1) our
choice to conduct all test sessions in the morning when circadian effects on the HPA axis
may override stress and cycle effects (Kudielka, Schommer, Hellhammer, & Kirschbaum,
2004); 2), the absence of a measure of free (biologically available) cortisol, which may have
obscured our ability to observe a menstrual cycle influence on cortisol since estradiol
influences corticotropin binding globulin (CBG) levels (Kirschbaum et al., 1999); and 3)
since cortisol and ACTH were measured only once post-task, this may have limited our
ability to capture the dynamic activation of the HPA axis during and following mental stress.
It should also be acknowledged that the relatively young and narrow age range of the study
participants may limit the generalizability of the current findings to other reproductive
phases when estradiol and progesterone are particularly dynamic (e.g., puberty and during
the menopause transition). Additionally, because we did not assess subjective mood during
the TSST, we could not assess the effects of subjective responses to stress on physiologic
stress reactivity. Lastly, because half of the sample was exposed to pain testing prior to
mental stress testing, the possibility exists that there may have been carryover effects of
pain-induced stress reactivity that could have influenced stress reactivity to the TSST.
However, because the order of pain versus stress testing was held constant for each subject
there is no reason to believe that the menstrual cycle effects on stress reactivity would have
been confounded by the order of events. Moreover, the 15-minute recovery between pain
and stress testing was imposed to minimize carry over effects.
In conclusion, while this study showed that myocardial and vascular determinants of BP
reactivity vary with menstrual cycle phase, it also suggests that these hemodynamic
determinants are more directly influenced by EPI reactivity to stress than by endogenous sex
hormones. By and large, cardiovascular stress reactivity in these medically and
psychologically healthy women is remarkably stable throughout the menstrual cycle. The
hemodynamic shifts in CI and VRI reactivity that were observed across phases may
represent an adaptive mechanism aimed at keeping BP reactivity relatively constant. Taken
together, the hemodynamic response profile observed during the luteal phase of the
menstrual cycle, of enhanced CI reactivity but greater vasodilation to preserve stable BP
reactivity, a profile seen in groups at lower risk for CVD (Allen et al., 1993; Girdler et al.,
1990; Light et al., 1993; Sherwood et al., 2010; Treiber et al., 2000), may be one mechanism
by which the female sex hormones confer cardio protection in premenopausal women. This
is not to say, however, that there may not be subgroups of women for whom hemodynamic
mechanisms fail to maintain stable BP reactivity across the menstrual cycle. Future studies
examining menstrual cycle influences on cardiovascular and neuroendocrine reactivity in
women at higher risk for CVD, such as women who suffer from obesity or who have a
strong family history of CVD, are warranted.
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Table 1
Demographic and baseline characteristics.
Mean (SD) or %
Age (yrs) 27.5 (0.8)
BMI (kgs/m2) 26.9 (0.8)
Race
  % Caucasian 60
  % African American 31
  % Other 9
BDI Score 3.0 (0.4)
Spielberger Trait Anxiety 31.7 (6.5)
Spielberger State Anxiety 27.8 (5.9)
Estradiol (ng/ml)
  Early follicular 23.3 (6.4)
  Late follicular 44.6 (22.6)
  Luteal 54.5 (22.4)
Progesterone (ng/ml)
  Early follicular 0.2 (0.1)
  Late follicular 0.2 (0.2)
  Luteal 13.7 (7.8)
BMI, body mass index; BDI, Beck Depression Inventory
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Table 2
Mean (SD) baseline cardiovascular and neuroendocrine measures as a function of menstrual cycle phase.
Early Follicular Late Follicular Luteal
SBP (mmHg) 110.6 (10.4) 109.6 (10.8) 111.3 (10.5)
DBP (mmHg) 65.5 (7.7) 63.7 (8.1) 64.6 (6.8)
HR (bpm) 69.0* (9.4) 68.2# (10.4) 71.2*# (8.1)
CI (l/min) 4.2 (1.2) 4.3 (1.1) 4.4 (1.4)
SVI (ml/beat per M2) 62.7 (19.0) 64.8 (18.0) 62.4 (18.8)
VRI (dyne s cm−5 M2) 515.0* (167.6) 484.6 (146.0) 484.9* (126.6)
Epinephrine (pg/ml) 10.7 (8.0) 11.1 (7.1) 11.4 (8.4)
Norepinephrine (pg/ml) 172.8 (64.4) 172.3 (68.6) 190.8 (71.3)
Cortisol (pg/ml) 6.8 (2.3) 6.9 (2.3) 6.2 (2.5)
ACTH (pg/ml) 21.4 (10.3) 21.4 (11.2) 19.2 (6.5)
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; SVI, stroke volume index; VRI, vascular resistance index; ACTH,
adrenocorticotropic hormone;
Note: Values in the same row with the same superscript (* or #) are significantly different from each other at the p<.05 level
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Table 3
Mean (SD) reactivity during mental stress as a function of menstrual cycle phase.
Early Follicular Late Follicular Luteal
SBP (mmHg)
  Speech 22.0 (9.7) 23.3 (9.3) 22.3 (9.3)
  Math 15.5 (8.2) 15.8 (8.6) 15.0 (8.5)
DBP (mmHg)
  Speech 16.3 (7.2) 16.6 (6.6) 14.8 (5.3)
  Math 11.2 (5.6) 11.6 (5.0) 11.1 (5.8)
HR (bpm)
  Speech 17.4 (8.7) 18.9 (8.8) 19.2 (10.0)
  Math 11.6 (5.7) 12.7 (7.1) 12.3 (6.4)
CI (l/min)
  Speech 1.1* (0.9) 1.2 (1.0) 1.4* (1.0)
  Math 0.6 (0.7) 0.6 (0.7) 0.6 (0.7)
SVI (ml/beat per M2)
  Speech −0.7 (10.3) −1.6 (10.1) 1.3 (10.8)
  Math −2.4 (7.4) −4.0 (7.7) −2.6 (7.9)
VRI (dyne s cm−5 M2)
  Speech −10.0 (113.2) 0.8* (86.0) −24.9* (91.2)
  Math 12.6 (85.7) 16.2 (87.3) 13.6 (77.1)
Epinephrine (pg/ml)
  Speech 11.7*& (13.8) 17.7* (26.2) 17.9& (23.2)
  Math 6.1 (10.1) 5.7 (10.3) 5.8 (9.8)
Norepinephrine (pg/ml)
  Speech 31.1 (44.4) 37.8 (45.2) 41.1 (46.8)
  Math 17.6 (46.5) 17.2 (53.4) 27.3 (42.7)
Cortisol (pg/ml) 0.2 (2.4) 0.0 (2.5) 0.1 (2.2)
ACTH (pg/ml) 1.4 (6.2) 1.6 (7.1) 1.0 (4.8)






Note: Values in the same row with the same superscript (* or &) are significantly different from each other
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